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Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an attractive target for new cholesterol-lowering drug
development. Here, we developed a method integrating ligand ﬁshing, HPLC-Q-TOF-MS and interdisciplinary assay,
aiming to explore potential PCSK9 inhibitors from mixtures rapidly and accurately. PCSK9 was expressed and puriﬁed
ﬁrstly, and then the recombined PCSK9 was coated on the surface of magnetic beads (MBs). The PCSK9-immobilized
MBs (PCSK9-MBs) were used for ligand ﬁshing combined with HPLC and Q-TOF-MS/MS. Ginkgo biloba leaves (GBL),
an herbal medicine widely used in Asia and Europe with good efﬁcacy in treatment of hypercholesterolemia, were
chosen as an illustration for ligand ﬁshing. Two PCSK9 ligands were discovered from GBL and identiﬁed as kaempferol3-O-rutinoside (1) and kaempferol 3-O-2''-(6000 -p-coumaroyl) glucosylrhamnoside (KCGR) (2). In order to verify ﬁshing
results and pick out more powerful PCSK9 inhibitors, molecular docking assay was further performed and KCGR was
optimized to be an excellent PCSK9 inhibitor by the conﬁrmation of afﬁnity and activity bioassay. These results suggested that the developed approach could be applied to screen and analysis potential bioactive constituents from
mixtures, which may improve the efﬁciency of drug discovery. Moreover, KCGR separated from GBLwas expected to be
a potential candidate of PCSK9 inhibitors.
Keywords: Drug discovery, Ginkgo biloba leaves, Hypercholesterolemia, Ligand ﬁshing, PCSK9 inhibitor

1. Introduction

T

he hyperlipidemia is one of the risk factors
for cardiovascular disease, coronary atherosclerosis and stroke [1], causing prominent global
adult mortality. Currently, statin drugs were the
preferred choices for treating hyperlipidemia [2].
However, some patients suffered from familial
hypercholesterolemia (FH) did not achieve the
desired therapeutic effect even at maximal statin
dose [3,4]. The low-density lipoprotein receptor
(LDLR), which is expressed on the membrane

surface of hepatocytes, can bind to the low-density lipoprotein cholesterol (LDL-C) [5]. Then, the
complex of the LDLR/LDL-C collectively internalizes, after which the LDL-C is released and
degraded into lipids and amino acids. Whereafter, LDLR retures to the cell surface, which is
known as the recycling of LDLR [6]. However, the
proprotein convertase subtilisin/kexin type 9
(PCSK9) can couple with the cell-surface LDLR
and prevents its recycling, which promotes the
degradation of LDLR, and consequently causing
raised levels of plasma LDL-C in the patients with
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FH [7,8]. Many researches have indicated that
PCSK9 inhibitors could efﬁciently decrease the
plasma level of LDL-C by interrupting the
proteineprotein interaction of PCSK9/LDLR [5].
Therefore, searching for PCSK9 inhibitors would
be a new and imperative therapy for the development of cholesterol-lowing drugs. Although
three PCSK9 antibody-drugs have been approved
[9,10], the high cost and low compliance of antibody-drugs still caused the patients distressed.
Considering lower cost and ease of administration, oral PCSK9 inhibitors have been an alternative therapy desirable for development.
Ginkgo biloba leaves (GBL) agents are the most
widely used herbal supplements in recent years
[11,12]. Previous studies have indicated that GBL
had signiﬁcantly lipid-regulating effects on hyperlipidemia [13e15]. However, the mechanism of the
interaction between GBL and PCSK9, as well as the
main active compounds of GBL contributing to the
hypolipidemic effects remained unclear.
Taking advantages of good selectivity and high efﬁciency, several afﬁnity-based strategies such as cell
membrane chromatography [16], afﬁnity ultraﬁltration [17,18] and molecular docking [19], have been
frequently applied for screening bioactive compounds in herbal medicines. Ligand ﬁshing is a welldeveloped afﬁnity-based method in which ligands
can be separated from unbound components in mixtures by selective binding to target enzymes or receptors. In consideration of preservation for protein
activity and convenience in operating, magnetic
beads (MBs) have been extensively served as solid
supports for ligand ﬁshing. Up to now, several researches have been reported to use enzyme/protein
immobilized MBs to identify active compounds from
the herbal medicines, such as inhibitors of ACE [20]
and a-glucosidase [21]. However, to the best of our
knowledge, magnetic ﬁshing-LC-MS (MF-LC-MS)
method has not been reported for seeking PCSK9 ligands in herbal medicines or other complex mixtures.
In this study, a ﬁshing strategy was established
integrating MF-LC-MS and multidisciplinary activity detection to rapidly screen compounds for
inhibiting PCSK9 from a complex natural extract (as
shown in Fig. 1). PCSK9 was primarily immobilized
onto the surface of MBs. MBs immobilized with
PCSK9 (PCSK9-MBs) were then incubated with
natural extracts to catch the potential PCSK9 ligands.
Then, the unbound components were abandoned by
magnetic separation and washing. The ligand-target
complexes were obtained, and the bound components could be dissociated from the target by adding

organic denature reagents. The dissociated components were analyzed by LC/MS. The interaction between PCSK9 and the potential ligands would be
rapidly predicted by molecular docking to eliminate
non-speciﬁc binding in the ﬁshing period. Moreover,
cell assays combined with bio-layer interferometry
(BLI) binding assays were further conducted to ﬁnd
out potential inhibitors of the PCSK9 from the above
ligands. The feasibility of this method was evaluated
by a famous herbal medicine GBL for screening
potential PCSK9 inhibitors.

2. Methods
2.1. Apparatus, chemicals and reagents
The Ginkgo biloba leaves (GBL) were purchased
from Tong Ren Tang Industrial Corporation (Nanjing, China). The Ginkgo biloba leaves (GBL) were
dried, powdered. Voucher specimens of GBL were
identiﬁed and stored at 4  C in Jiangsu Key Laboratory of TCM Evaluation and Translational
Research, China Pharmaceutical University.
The reference standard of kaempferol-3-O-rutinoside was provided by Chengdu Herbpurify Co.,
Ltd (Chengdu, China). Formic acid of HPLC grade
was purchased from Aladdin Industrial Corporation
(Shanghai, China). Water was prepared by Milli-Q
water puriﬁcation system (Millipore, Bedford,
United States). Methanol and acetonitrile (ACN) of
HPLC grade were provided by Merck Company Inc.
(Darmstadt, Germany). All other chemicals and
solvents were of analytical grade.
Plasmid isolation and DNA puriﬁcation kits were
purchased from Transgene (Beijing, China). Isopropylthio-b-D-galactopyranoside (IPTG) was provided by Invitrogen (Beijing, China). Ni-NTA
afﬁnity resin was provided by Beyotime (Nanjing,
China). Amicon Ultra Centrifugal Filter Units
(30 kDa) were provided by Millipore (Bedford,
United States).
2.2. Preparation of PCSK9 coated magnetic beads
The preparation of PCSK9-MBs was carried out
according to our previous study with some alterations [22]. The human PCSK9 gene (152e692) was
codon-optimized to permit bacterial expression, and
the ﬁnal PCSK9 sequence was inserted into a
pET22b vector with the NdeI and XhoI sites, followed by transformation into Escherichia coliBL21
(DE3). Whereafter, the cells were incubated in TB
medium supplemented with 50 mg/mL ampicillin at
37  C. The recombinant protein expression was
induced by 0.1 mM IPTG and incubated at 20  C
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Fig. 1. The schematic diagram of the strategy for screening PCSK9 inhibitors from herbal medicines based on ligand ﬁshing integrated interdisciplinary assay.

overnight. The cells were centrifuged at 4000Хg for
10 min, and resuspended in 50 mM sodium phosphate (pH 8.0)/0.3 M NaCl. The cell pellets were
lysed by ultrasonication. After centrifuged, the
lysate containing recombinant PCSK9 was obtained.
Then, the lysate solution was ﬂowed through a NiNTA resin column to purify the PCSK9 protein with
a hexahistidine-tag (His-PCSK9), and the HisPCSK9 eluent was concentrated by ultraﬁltration to
0.5 mg/mL. All protein puriﬁcation steps were
conducted at 4  C as quickly as possible. Whereafter, we chose Ni magnetic beads to link PCSK9 by
the chelate action between Ni2þ and the His-tag.
The Ni beads (~10 mg) was mixed with 1 mL PCSK9
solution (50 mg/mL), and then rotated together in a
stirring mixer for 1 h at room temperature. Then, the
PCSK9-MBs were separated by magnetism and
rinsed by 100 mL wash buffer (20 mM Sodium
Phosphate, 500 mM NaCl, pH 7.4) to exclude the
non-speciﬁc adsorption. The PCSK9-MBs were
stored in PBS at 4  C for the next experiments. The
stability of PCSK9-MBs within 72 h was evaluated.
2.3. Optimization conditions for ligand screening
The preparation of the PCSK9-MBs was as the
above. To optimize the screening conditions, we

selected the SBC-115076, a PCSK9 inhibitor, as the
model drug [22]. The PCSK9-MBs (100 mL) were
incubated with SBC-115076 (1 mL, 100 mM) in PBS
for a period to enable the ligand (SBC-115076) to
bound to the PCSK9, and then the ligand-PCSK9MBs complexes were obtained by magnetic separation. The amount of SBC-115076 on the PCSK9MBs could be dissociated by adding 200 mL methanol, followed by analysis by HPLC-MS. In this
process, three parameters were optimized to obtain
the appropriate screening conditions. Different ionic
strength (10, 25, 50, 75, and 100 mM) of PBS, incubation temperature (4, 16, 25, and 37  C) and incubation time (0.5, 1, 2, 4, and 8 h) were evaluated.
2.4. Screening potential PCSK9 ligands from
Ginkgo biloba leaves by LC/MS
Ginkgo biloba leaves (GBL) were milled to powder. 1
g powdered GBL was ultrasonic extractedin50 mL 75%
v/v methanol twice for 1 h, and then ﬁltered. The extracts of GBL were vacuum-evaporated to dryness and
dissolved with 1 mL dimethyl sulfoxide (DMSO) to
form the test solution. The test solution were store at
20  C.
After the PCSK9-MBs were prepared, the following
process of ligand ﬁshing consists of four steps: ligand
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adsorption, magnetic separation, ligand elution, and
characterization. The procedure of ligand screening
was conducted as the described above (Fig. 1). PCSK9MBs (100 mL) was incubated with the extract of GBL
(1 mL) in the PBS (200 mL, 75 mM, pH 7.4) for 2 h, and
then conducted magnetic separation. The obtained
ligand-PCSK9-MBs complexes were added 200 mL
methanol, shaked, ﬁltered, and followed by analysis
by HPLC-MS. Experiments were also set to use beads
coating the denatured PCSK9 which were boiled in
water for 10 min. A blank control only incubated of
PCSK9-MBs without the addition of GBL was conducted. The ligands would be captured by the ligand
ﬁshing and identiﬁed by HPLC-MS/MS.
HPLC-Q-TOF-MS/MS was performed on an
Agilent 1260 series HPLC system coupled with an
Agilent 6530 Q-TOF mass spectrometer equipped
with an electrospray ionization (ESI) source. An
Agilent
ZORBAX
SB-C18
column
(4.6 mm  250 mm, 5 mm) was used for sample
separation. The ﬂow rate was 0.8 mL/min, and the
column temperature was maintained at 35  C. The
mobile phase was water-formic acid (100:0.1, A) and
acetonitrile (B) using a gradient elution program of
0e20 min, 10%e30% B; 20e45 min, 30%e70% B;
45e52 min, 70%e95% B; 52e55 min, 95-95% B. The
detection wavelengths were 203 nm, 254 nm,
280 nm, 310 nm, and 365 nm. The sample volume
injected was 20 mL.
The ESI-MS acquisition conditions were in negative modes set as follows: The mass range was
scanned from m/z 100e1500 with collision energy
(CE) from 10 eV to 50 eV N2 ﬂow rate was set as
10.0 L/min at 350  C; nebulizer pressure at 35 psig;
capillary voltage at 3500 V; OCT RFV at 750 V; and
fragmentor voltage at 120 V. The TOF mass spectrometer was calibrated every day before sample
analysis for guaranteeing mass accuracy. The data
acquisition and analysis were controlled by Agilent
Mass Hunter Workstation software version B.07.00.
2.5. Molecular docking
To rapidly predict the potential ability of ligands
above, molecular docking of the ligand-target
interaction was conducted with the Molecular
Operating Environment (MOE.2009.10) software.
The protein structure of PCSK9 was downloaded
from the Protein Data Bank (PDB code: 3gcx). The
compounds were drawn and protonated in MOE,
and the three-dimensional structure of PCSK9 was
removed the ligands, water molecules, and metal
ions before docking. The compounds were docked
into the binding sites of the PCSK9 respectively after
the energy was minimized. The poses of molecules

were obtained and scored using ASE scoring
function.
2.6. Cell culture
HepG2 cells (ATCC) were grown in DMEM supplemented with 10% (v/v) FBS, streptomycin (50 g/
mL), L-glutamine (2 mM) and penicillin (50 U/mL).
HepG2 cells were incubated in six multi-well plates
for 12 h at 37  C. For different treatments, cells were
divided into four groups. Before the addition to
cells, ligands at different concentrations (0, 0.5, 1.5,
5.0 mM) were incubated with PCSK9 (15 mg/mL) for
30 min in the presence of 0.5% DMSO. Then, the
cells above were incubated for 24 h.
2.7. Western blot analysis of cell LDL receptor
Cells were lysed with RIPA lysis buffer and proteins were harvested. Total cell protein extracts were
separated by 8% SDS-PAGE gel, and then transferred onto 0.22 mm PVDF membranes (Millipore).
The protein on PVDF membranes were blocked
with 5% BSA-TBST at room temperature for 2 h.
Then, the PVDF membranes were incubated with
anti-LDLR (1:4000; abcam) and anti-GAPDH (1:4000;
Sigma) antibodies at 4  C overnight, respectively.
After washed three times with TBST, the membranes were then incubated with HRP-conjugated
anti-rabbit IgG (1:4000; Cell Signaling Technology)
for 2 h at room temperature. The immunoreactive
bands were detected using ECL reagents by Bio-rad
Gel Imaging System. The protein was quantiﬁed
based on the intensity of bands by the Image Lab
analysis software and normalized to the internal
protein GAPDH. All experiments were performed
in triplicate.
2.8. Bio-layer interferometry binding assays
Binding kinetics of the ligand-PCSK9 interaction
were determined by the bio-layer interferometry
(BLI) method. All experiments were conducted in
PBS buffers (pH 7.4) using Octet RED96 system
(Fort
eBio) at 25  C. His-PCSK9 was immobilized
onto Ni-NTA biosensors, and then the proteincoated biosensors were used to measure the process
of association and dissociation with a time window
of 300 and 180 s, respectively. There were two control tests measured in parallel for double referencing corrections: protein-coated biosensors alone,
and uncoated biosensors with compounds at corresponding concentrations. The binding constants
were calculated by subtracted binding interference
data with the ForteBio analysis software.

2.9. Statistical analysis
All experiments were performed in triplicate.
Statistical analysis was performed using GraphPad
Prism 6.0 Software (San Diego, CA, USA). Data are
presented as the mean ± SEM. Group comparisons
were assessed with the two-tailed Student's t-test or
ANOVA with Bonferroni's post hoc test for comparison of multiple columns. A value of P < 0.05 was
considered as statistically signiﬁcant.

3. Results and discussion
3.1. Preparation and characterization of the
PCSK9-MBs
The main function of secreted PCSK9 is inducing
the degradation of LDLR. The catalytic domain and
the C-terminal domain of PCSK9 are two important
domains for the PCSK9/LDLR interaction, leading
to the degradation pathway of LDLR [23e26].
Considering the bioactive function of reconstituted
His-PCSK9, the catalytic domain and C-terminal
domain of human PCSK9 were selected to be
expressed as targets for ligands ﬁshing. As our
previous study [22], the protein (His-PCSK9) was
expressed and puriﬁed with a hexahistidine tag at
the N-terminus (Fig. S1). The puriﬁed His-PCSK9
had the characterization for inducing LDLR degradation, which indicated that reconstituted HisPCSK9 maintained the bioactive function of the
prototype PCSK9 (Fig. S2). Then, the His-PCSK9
were coupled to the magnetic beads as described
above, and the preparation procedures of PCSK9MBs were repeatable. PCSK9-MBs could remain
more than 72 h (Table S1).
3.2. Optimization of ligand ﬁshing conditions
The ligand ﬁshing method based on PCSK9MBs, was veriﬁed and optimized using one
known compound, SBC-115076, which was the
positive inhibitor of PCSK9. To guarantee the
appropriate screening conditions of the active
components in mixtures, three important parameters were optimized, including incubation time,
incubation temperature and PBS ionic strength
[27]. Incubation times between 0.5 and 8 h were
tested using SBC-115076 (Fig. 2A). With excess
SBC-115076, 2 h was the appropriate time for the
ligandseprotein interaction. Incubating for a long
time may cause the denaturation of PCSK9 or
disassembly of PCSK9 MBs, leading to lower
binding degrees. Considering the properity of
PCSK9 and the stability of PCSK9-MBs, the
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incubation pH was chosen as the normal physiological the pH 7.4. 25  C was demonstrated as
the most suitable temperature for the ligand
binding (Fig. 2B). The ionic strength of the
binding buffer may impact on the charge distribution on the protein surfaces. As shown in
Fig. 2C, the proper ionic strength was 75 mM.
With the increase of the ion strength, the concentration of ions was exceeded, which might
reverse the effect of ions, resulting in lower
binding degrees. From the above, the parameters
were optimized as follows: incubation at 25  C for
2 h, and ionic concentration 75 mM (pH 7.4).
3.3. PCSK9 ligand ﬁshing of Ginkgo biloba leaves
and HPLC-Q-TOF-MS/MS analysis
According to the optimized conditions above, we
screened the potential ligands of PCSK9 from GBL
using HPLC-Q-TOF-MS/MS. The chromatograms
of screening results were shown in Fig. 3. Compared
with HPLC spectrums at different wavelengths, we
chose 280 nm as the detection wavelength, which
may reveal the difference between the peak areas
with and without the PCSK9 incubation more
distinct and undisturbed. The UV peak areas of two
components were demonstrated to be signiﬁcantly
higher in the group incubated with PCSK9-MBs
than the control group. Based on our strategy, these
two components were regarded as the major potential ligands binding to the PCSK9, which were
considered to apply for follow-up study. The afﬁnity
compounds were subsequently identiﬁed exactly by
comparing with standards and published data.
Considering that the intensities of negative ion signals exhibited higher than that of positive ion signals, we selected the negative ion mode for MS
assay. The HPLC and MS data of two compounds (1
and 2) were listed in Table 1.
For Compound 1, it was identiﬁed as kaempferol3-O-rutinoside by compared with the standard
compound (Fig. S3). The formula of compound 1
was calculated as C27H30O15 based on the molecular
ion at m/z 593.1505. The negative mode MS/MS
product ions m/z 447 and 285 were assigned as [MH-Rutinose] and [M-H-Rutinose-glu]. The other
fragment ions were at m/z 327 ([M-H-RutinoseC4H8O4]-)
and
m/z
255
([M-H-RutinoseglueCOeH2]-). The fragment ions m/z 285 could
further produce ion m/z 151 by the retro-DielseAlder (RDA) reaction. The formula of compound
2 was calculated as C36H36O17 based on the molecular ion at m/z 739.1889. In the MS/MS spectra,
fragment ions at m/z 593 and 284 were produced by
successive neutral losses of 146 Da (Coumaroyl) and
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Fig. 2. The parameter optimization of the incubation time (A), temperature (B) and ionic strength of PBS (C) on the binding properties of ligands to
PCSK9. SBC-115076 was the model compound.

308 Da (rha þ glu) (Fig. S4). The other fragment ions
were
at
m/z
255
([M-H-Coumaroyl-rhaglueCOeH2]-) and m/z 145 ([Coumaroyl-H]-).
Compound 2 was subsequently isolated and puriﬁed (Fig. S5), and determined with NMR (Fig. S6).
By comparing the HPLC-MS/MS and NMR data

with the reference [28], compound 2 was identiﬁed
to be kaempferol 3-O-2''-(6000 -p-coumaroyl) glucosylrhamnoside (KCGR). The chemical structures of
compound 1 and 2 were shown in Fig. 3B. They are
both classiﬁed into ﬂavonoid compounds. According to the previous study, the amount of compound

Fig. 3. (A) The comparison HPLC chromatograms of the PCSK9 ligand ﬁshing in the Ginkgo biloba leaves (GBL) at 280 nm. (a) represents the HPLC
proﬁle of the extract of GBL; (b) represents the HPLC proﬁle when the GBL incubated with active PCSK9-MBs; (c) represents HPLC proﬁle when the
GBL incubated with inactive PCSK9-MBs; (d) represents the HPLC proﬁle of the blank control which was only incubated of PCSK9-MBs without the
addition of GBL. The screened ligands are labeled above the peaks with numbers. (B) Chemical structures of ﬁshed compounds 1 and 2, which were
kaempferol-3-O-rutinoside and kaempferol 3-O-2''-(6000 -p-coumaroyl) glucosylrhamnoside (KCGR), respectively.

Table 1. Retention times, UV absorption maxima and MS data of afﬁnity compounds on PCSK9 from Ginkgo biloba leaves by HPLC-MS/MS.
Peak NO.

RT (min)

UVmax (nm)

[MH]m/z

Cal m/z

Diff (ppm)

Fragment

Formula

Identification
Kaempferol 3-O-200 glucosylrhamnoside[a]
Kaempferol 3-O-2''-(6000 -pcoumaroyl) glucosylrhamnoside

1

19.908

266, 344

593.1505

593.1512

1.17

285.0397,151.0017

C27H30O15

2

23.627

266, 316

739.1889

739.1880

1.25

593.1510,413.0890,
284.0328,145.0290

C36H36O17

[a] Compared with standard compounds.

1 and 2 present in the extract of Ginkgo biloba
leaves were 13.08e15.06 mg/g and 20.12e25.21 mg/
g, respectively [29].
3.4. Molecular docking
Parallel assays by setting the control group could
be applied to eliminate the false positive, but the
repeated operation was indubitably inefﬁcient. The
molecular docking was promised to be alternated
for excluding the non-speciﬁc afﬁnity. Thus, we
used the molecular docking assay to predict binding
sites and potential activity of two possible ligands,
which may contribute to seeking out the potential
inhibitors of the PCSK9 rapidly. The results were
evaluated according to the docking poses and the
ligandeprotein interactions [30]. The binding energies and afﬁnity of ligands to PCSK9 were summarized in Table 2.
In consideration of binding energy and afﬁnity,
KCGR (compound 2) was preferred with signiﬁcantly lower binding energy (14.4342 kcal/mol)
and higher afﬁnity (6.68 pKi) than the positive control SBC-115076 (10.0054 kcal/mol, 5.83 pKi). The
protein-ligand interaction between KCGR and the
PCSK9 were presented in Fig. 4. Four hydrogen
bonding were formed between KCGR (compound 2)
and PCSK9 at the Asp 374, Ser 372 and Ser 221
(Fig. 4B). Besides, the other compound (compound
1) was also predicted to have certain interactions
with PCSK9, such as Phe 379 and Thr 377 (Fig. S7),
but its binding afﬁnity was relatively inferior to that
of KCGR and SBC-115076, which might possess
slightly weak activity. The previous research has
reported that the structures of kaempferol and pcoumaric acid might contribute to the PCSK9 inhibition [31], which was consistent with our research.

Table 2. The binding energies and afﬁnity of PCSK9 ligands by molecular docking assay.
Name

Binding energies (kcal/mol)

Affinity (pKi)

SBC-115076
1
2

10.0054
13.6614
14.4342

5.83
5.07
6.68

Moreover, our study further investigated and clariﬁed the interaction between ligands and PCSK9.
From the above, with molecular docking, compounds 2 beared signiﬁcant protein afﬁnity. However, molecular docking assay is a virtual approach
to predict the afﬁnity between ligands and the
target, so the activities of ligands were still needed
to be conﬁrmed by activity assays, which could also
validate the established method.
3.5. PCSK9 inhibitory activity of afﬁnity ﬁshing
compounds
The results of cell assay indicated that both compounds 1 (IC50 ¼ 0.4993 mM) and 2 (IC50 ¼ 0.1837 mM)
could suppress the PCSK9-induced LDLR degradation in HepG2 cells in a concentration-dependent
manner (Fig. 5). At the tested concentration of 5 mM,
the expression of LDLR in the group incubated with
compound 1 could restore to about 90% of control
levels (Fig. 5B). Fortunately, compound 2 demonstrated higher activity than that of compound 1. The
LDLR levels in the group incubated with compound
2 were restored and reached higher than that in the
control group at the concentration of 5 mM (Fig. 5C).
Compound 2 also showed the prominent inhibitory
activity better than that of positive control SBC115076 (Fig. 5A), which reminded that it deserved
further studied as the potential drug candidate.
Kaempferol glycosides are very common natural
products from plants, which were widely studied for
their ability on improvement of the LDLR expression. The related study has reported that kaempferol
could stimulate gene expression of LDLR through
activation of Sp1 in cultured hepatocytes [32]. Besides this, a new mechanism might be proposed in
our study about the kaempferol glycosides which
could interact with PCSK9 for increasing the
expression of LDLR.
Binding thermodynamic and kinetics have
deemed as important design parameters for inhibitors. Therein, slow binding off-rates were
considered to be related to improved inhibitor efﬁcacies due to prolonged effects on the target in vivo
[33]. So, we further detected the kinetic aspects of
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Fig. 4. The Spatial (A) and two-dimension (B) structures of the microenvironment interaction between KCGR and PCSK9 (PDB: 3gcx) generated with
MOE. The atom colors of the KCGR and the residues of PCSK9 were grey and green, respectively.

the compound 2 (KCGR) interacted with PCSK9
using bio-layer interferometry (BLI) analysis. BLI
experiments were conducted at pH 7.4 and the KD
values for KCGR was obtained. Interestingly, we
observed slow dissociation rates of KCGR when
binding to PCSK9 (Fig. 5D). Commonly, slower kinetics has been considered as a characteristic of

some type-II allosteric inhibitors possibly due to
kinetic constrains of the necessary structural rearrangements [34,35], resulting in KD values in the low
nanomolar range (KD ¼ 15 nM). The low KD value
reminder that compound 2 (KCGR) could be
considered as a candidate PCSK9 inhibitor for the
pharmaceutical development.

Fig. 5. The inhibitory activities of the ﬁshed compounds on PCSK9. The potency of SBC-115076 (A), compound 1 (B) and compound 2 (C) for
restoring LDLR levels on the PCSK9-treated HepG2 cells. The expression levels of LDLR on HepG2 cells were semiquantitated by Western blot assay.
The values are the mean ± SEM deviation of the three independent experiments. #p < 0.05; ##p < 0.01; compared with the control group, *p < 0.05;
**p < 0.01, compared with the PCSK9 group. (D). The BLI sensogram showing the process of association and dissociation at different concentrations
(0, 50, 100, and 200 mM) for the interaction of compound 2 (KCGR) with PCSK9.

4. Conclusions
In conclusion, an effective strategy integrating
ligand ﬁshing, molecular docking, binding assay
and inhibitory activity assay was developed for
screening PCSK9 inhibitors from GBL, which was
demonstrated to be valid and practicable. On the
basis of our strategy, two compounds were ﬁshed
out from GBL, including kaempferol 3-O-200 -glucosylrhamnoside (compound 1) and kaempferol 3-O2''-(6000 -p-coumaroyl) glucosylrhamnoside (KCGR,
compound 2). KCGR was determined to exhibit
signiﬁcant inhibitory activity against PCSK9. Our
study provides the basis for further exploration of
active compounds from GBL in the intervention and
prevention of the PCSK9-related diseases for future
clinical use. Moreover, with the properties of targeted screening and accurate analysis, this strategy
is supposed to be further served for an extended
range to rapidly screen active ingredients from
mixtures, which will expedite the efﬁciency of drug
discovery.
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